Company intelligence / Profile preview

ProFuse Technology

Kiryat Shmona, Northern District, Israel

Ownership: Private
Employees: ~25
Development stage: Other

Overview

ProFuse Technology has developed a platform enabling mature human muscle tissue cultivation in vitro, with applications in drug discovery for muscle preservation and regeneration. Their technology is used to identify candidates for muscle-loss prevention, particularly in the context of aging and side effects of GLP-1 drugs. Current development is at preclinical/animal testing stages, with plans for Phase 1 licensing upon candidate identification.

Therapeutic areas: OncologyEndocrinologyMetabolic Disorders
Modalities: Small moleculeBiologicMedia supplement
Industry: Biotech

Partnerships

SuperMeat (cultivated meat sector)

Beyond the preview

Go deeper on ProFuse Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProFuse Technology.

Explore the full profile